US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Mirna Therapeutics

1.71

+0.02001.18%

Volume:40.94K

Turnover:70.00K

Market Cap:35.67M

PE:-1.35

High:1.75

Open:1.73

Low:1.65

Close:1.69

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Mirna Therapeutics

Exchange:

NASDAQ

Establishment Date:

- -

Employees:

- -

Office Location:

- -

Website:

http://www.mirnarx.com

Zip Code:

- -

Phone:

- -

Fax:

- -

Introduction:

Mirna Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of microRNA-based oncology therapeutics. The company is developing mimics of naturally occurring microRNAs (miR) that are designed to restore tumor suppressor activity and aid appropriate anti-tumor immune response. Its lead product candidate is MRX34, a mimic of naturally occurring microRNA-34 encapsulated in a liposomal nanoparticle formulation which is in Phase 1 clinical trial for the treatment of cancer. The companys preclinical product candidates include miR-215 for the treatment of esophageal, kidney, and multiple myeloma cancers; miR-101 for the treatment of bladder, gastric, lung, and ovarian cancers; miR-16 for the treatment of chronic lymphocytic leukemia and lymphoma cancers; and let-7 for the treatment of prostate, pancreatic, and melanoma cancers. It has strategic partnerships and license agreements with Asuragen, Inc.; Marina Biotech, Inc.; the Yale University; the University of Zurich; Rosetta Genomics Ltd.; the Cancer Prevention and Research Institute of Texas; and Polymun Scientific Immunbiologische Forschung GmbH. The company was founded in 2007 and is headquartered in Austin, Texas. Mirna Therapeutics, Inc. operates as a subsidiary of Asuragen, Inc.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MIRN/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MIRN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MIRN\",,,,,undefined,":{"symbol":"MIRN","market":"US","secType":"STK","nameCN":"Mirna Therapeutics","latestPrice":1.71,"timestamp":1503691200000,"preClose":1.69,"halted":4,"volume":40937,"delay":0,"floatShares":0,"shares":20859000,"eps":-1.27,"marketStatus":"Delisted","change":0.02,"latestTime":"04-25 05:53:34 EDT","open":1.7265,"high":1.75,"low":1.65,"amount":70002.27,"amplitude":0.059172,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.27,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1745587800000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":1.69,"volumeRatio":11.029475},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MIRN\",,,,,undefined,":{"symbol":"MIRN","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":11.029475,"shares":20859000,"dividePrice":0,"high":1.75,"amplitude":0.059172,"preClose":1.69,"low":1.65,"week52Low":1.12,"pbRate":"0.76","week52High":3.12,"institutionHeld":0,"latestPrice":1.71,"eps":-1.27,"divideRate":0,"volume":40937,"delay":0,"ttmEps":-1.27,"open":1.7265},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.mirnarx.com","stockEarnings":[{"period":"1week","weight":-0.8571},{"period":"1month","weight":-0.8571},{"period":"3month","weight":-0.8571},{"period":"6month","weight":-0.8571},{"period":"1year","weight":-0.8571},{"period":"ytd","weight":-0.8571}],"compareEarnings":[{"period":"1week","weight":0.0385},{"period":"1month","weight":-0.05},{"period":"3month","weight":-0.1008},{"period":"6month","weight":-0.0559},{"period":"1year","weight":0.0817},{"period":"ytd","weight":-0.0672}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Mirna Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of microRNA-based oncology therapeutics. The company is developing mimics of naturally occurring microRNAs (miR) that are designed to restore tumor suppressor activity and aid appropriate anti-tumor immune response. Its lead product candidate is MRX34, a mimic of naturally occurring microRNA-34 encapsulated in a liposomal nanoparticle formulation which is in Phase 1 clinical trial for the treatment of cancer. The companys preclinical product candidates include miR-215 for the treatment of esophageal, kidney, and multiple myeloma cancers; miR-101 for the treatment of bladder, gastric, lung, and ovarian cancers; miR-16 for the treatment of chronic lymphocytic leukemia and lymphoma cancers; and let-7 for the treatment of prostate, pancreatic, and melanoma cancers. It has strategic partnerships and license agreements with Asuragen, Inc.; Marina Biotech, Inc.; the Yale University; the University of Zurich; Rosetta Genomics Ltd.; the Cancer Prevention and Research Institute of Texas; and Polymun Scientific Immunbiologische Forschung GmbH. The company was founded in 2007 and is headquartered in Austin, Texas. Mirna Therapeutics, Inc. operates as a subsidiary of Asuragen, Inc.","exchange":"NASDAQ","name":"Mirna Therapeutics","nameEN":"Mirna Therapeutics"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"MIRN\",market:\"US\",,,undefined,":null,"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MIRN\",params:#limit:5,,,undefined,":[{"date":"2017-08-28","symbol":"MIRN","type":"split","dateTimestamp":1503892800000,"forFactor":7,"toFactor":1},{"date":"2017-08-28","symbol":"MIRN","newSymbol":"SYBX","type":"symbolChange","dateTimestamp":1503892800000},{"market":"US","date":"2017-08-04","symbol":"MIRN","fiscalQuarterEnding":"2017/06","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1501819200000,"reportTimeType":"","actualEps":-0.45},{"market":"US","date":"2017-05-09","symbol":"MIRN","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1494302400000,"reportTimeType":"","actualEps":-0.12},{"market":"US","date":"2016-11-10","symbol":"MIRN","fiscalQuarterEnding":null,"expectedEps":-0.32,"name":null,"time":"","type":"earning","dateTimestamp":1478754000000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MIRN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MIRN\",market:\"US\",delay:false,,,undefined,":{}}}